EASTERN COOPERATIVE ONCOLOGY GROUP

约翰霍普金斯自1955年以来一直是ECOG的成员。我们的首要 目标是带来创新的临床研究方案， 在约翰霍普金斯进行的与ECOG相关的实验室研究 进一步发展。与此同时，我们提供 作为方案研究主席的领导，以疾病和模式为导向 委员会主席以及委员会广泛参与 成员级别。 补助金展期的具体目标是：（1） 继续在以疾病为导向的 委员会：肺部、头颈部、乳腺、病理学和药理学 并将这些努力扩展到艾滋病和神经肿瘤学;（2） 将转化研究、细胞生物学和分子生物学 用于所有疾病阶段的临床方案， 预防;（3）扩大我们的权责发生制，改善数据管理; (4)以增加我们的附属社区的参与 医院的 我们期望通过以下方面的努力， 我们的教师在获得资助的实验室科学和临床 研究补助金，如肺和前列腺的SPORE补助金 癌症和我们继续与NCI的第一阶段合同。这些 赠款将允许开展I期临床试验， 包括骨髓移植、基因治疗和新的 细胞毒性药物，在约翰霍普金斯，然后可以采取， 用于疾病特异性II期和III期评价的ECOG。 新 约翰霍普金斯参与的领域包括艾滋病淋巴瘤和神经- 肿瘤科建立机制，将创新研究 将这两个领域的项目纳入西非经共体。 我们的研究成果， 数据管理质量将大大提高。这将是 通过对我们的数据管理进行全面重组， 新的行政人员办公室，一个新的ECOG专门研究 护士和一名新的高级数据管理协调员。利息是 由于临床项目的扩大， 我们计划在约翰霍普金斯建立一个新的更大的癌症中心。 此外，一位新的社区方案主任已被任命为 我们的目标是扩大我们的医院网络， "提供更多的机会，以获得高优先西非经共体-国家儿童基金会赞助的 包括癌症控制和预防研究。

Johns Hopkins has been a member of ECOG since 1955. Our primary goal is to bring innovative clinical research protocols and laboratory correlative studies piloted at Johns Hopkins to ECOG for further development. In conjunction with this, we provide leadership as protocol study chairs, disease and modality oriented committee chairs, as well as wide committee participation at the membership level. The specific aims during this grant renewal period are to: (1) continue to provide scientific leadership in the disease oriented committees: Lung, Head and Neck, Breast, Pathology and Pharmacology and to expand these efforts into AIDS and Neuro-Oncology; (2) to bring translational research, cell biology and molecular biology into clinical protocols for all stages of disease including prevention; (3) to expand our accrual and improve data management; (4) to increase participation of our affiliated community hospitals. We expect to achieve these aims through the successful efforts of our faculty in obtaining funded laboratory science and clinical research grants such as the SPORE grants in Lung and Prostate Cancer and our continuing Phase I Contract with the NCI. These grants will allow the development of phase I clinical trials, including bone marrow transplant, gene therapies, and novel cytotoxic agents, within Johns Hopkins that can then be taken to ECOG for disease-specific phase II and phase III evaluation. New areas of Johns Hopkins involvement include AIDS lymphoma and Neuro- Oncology. Mechanisms are in place to bring innovative research projects in these 2 areas into ECOG. Our accrual to studies and quality of data management will improve greatly. This will be accomplished through a total reorganization of our data management office with new administrative staff, a new ECOG dedicated research nurse, and a new senior data management coordinator. Accrual is expected to increase because of expanded clinical programs and faculty as we plan for a new larger Cancer Center at Johns Hopkins. In addition, a new director of Community Programs has been appointed with the specific goal of expanding our hospital network 'to provide greater access to high priority ECOG-NCI sponsored trials including cancer control and prevention studies.